Latest Insider Transactions at Quanterix Corp (QTRX)
This section provides a real-time view of insider transactions for Quanterix Corp (QTRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Quanterix Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Quanterix Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
10,718
+18.5%
|
$203,642
$19.12 P/Share
|
|
Nov 04
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
1
-0.0%
|
$57
$57.0 P/Share
|
|
Nov 02
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
331
-0.5%
|
$17,212
$52.77 P/Share
|
|
Nov 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,505
-0.19%
|
$182,260
$52.77 P/Share
|
|
Nov 02
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
333
-0.45%
|
$17,316
$52.77 P/Share
|
|
Nov 02
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
139
-0.3%
|
$7,228
$52.77 P/Share
|
|
Oct 22
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.18%
|
$250,000
$50.94 P/Share
|
|
Oct 15
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.89%
|
$85,017
$51.47 P/Share
|
|
Oct 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
269
+1.89%
|
$13,719
$51.18 P/Share
|
|
Oct 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
354
+2.25%
|
$18,054
$51.18 P/Share
|
|
Oct 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
232
+1.91%
|
$11,832
$51.18 P/Share
|
|
Oct 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
143
-0.6%
|
$7,293
$51.2 P/Share
|
|
Oct 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
342
-0.92%
|
$17,442
$51.2 P/Share
|
|
Oct 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
340
-1.02%
|
$17,340
$51.2 P/Share
|
|
Oct 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
254
+0.26%
|
$12,954
$51.18 P/Share
|
|
Oct 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,594
-0.39%
|
$183,294
$51.2 P/Share
|
|
Sep 30
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$240,000
$48.38 P/Share
|
|
Sep 22
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.57%
|
$78,349
$47.72 P/Share
|
|
Sep 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$245,000
$49.95 P/Share
|
|
Sep 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,709
-0.2%
|
$185,450
$50.26 P/Share
|
|
Sep 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
353
-0.47%
|
$17,650
$50.26 P/Share
|
|
Sep 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
350
-0.52%
|
$17,500
$50.26 P/Share
|
|
Sep 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
147
-0.31%
|
$7,350
$50.26 P/Share
|
|
Aug 20
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.27%
|
$76,682
$46.13 P/Share
|
|
Aug 17
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,954
+9.42%
|
-
|
|
Aug 17
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
310,000
-34.06%
|
-
|
|
Aug 16
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$235,000
$47.62 P/Share
|
|
Aug 10
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,952
+10.39%
|
-
|
|
Aug 10
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
310,000
-25.4%
|
-
|
|
Aug 03
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
145
-0.6%
|
$7,685
$53.79 P/Share
|
|
Aug 03
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
346
-0.91%
|
$18,338
$53.79 P/Share
|
|
Aug 03
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
344
-1.01%
|
$18,232
$53.79 P/Share
|
|
Aug 03
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,648
-0.39%
|
$193,344
$53.79 P/Share
|
|
Jul 29
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.27%
|
$270,000
$54.03 P/Share
|
|
Jul 14
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.01%
|
$95,019
$57.77 P/Share
|
|
Jul 13
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.26%
|
$285,000
$57.55 P/Share
|
|
Jul 12
2021
|
Michael A Doyle CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
5,530
+50.0%
|
-
|
|
Jul 02
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
146
-0.2%
|
$8,468
$58.46 P/Share
|
|
Jul 02
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
346
-0.34%
|
$20,068
$58.46 P/Share
|
|
Jul 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,658
-0.13%
|
$212,164
$58.46 P/Share
|
|
Jul 02
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
347
-0.3%
|
$20,126
$58.46 P/Share
|
|
Jul 01
2021
|
Laurie J Olson |
BUY
Grant, award, or other acquisition
|
Direct |
104
+2.19%
|
$6,136
$59.48 P/Share
|
|
Jul 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
231
+1.66%
|
$13,629
$59.48 P/Share
|
|
Jul 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
304
+1.99%
|
$17,936
$59.48 P/Share
|
|
Jul 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
199
+1.68%
|
$11,741
$59.48 P/Share
|
|
Jul 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
218
+0.29%
|
$12,862
$59.48 P/Share
|
|
Jul 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
8,454
-9.49%
|
$490,332
$58.49 P/Share
|
|
Jul 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
9,806
+17.36%
|
$215,732
$22.12 P/Share
|
|
Jun 23
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.77%
|
$103,354
$62.11 P/Share
|
|
Jun 15
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
696
-1.85%
|
$44,544
$64.33 P/Share
|